Saksoft, HDFC Life and Tata Motors to see some action today
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Saksoft has acquired Ceptes Software, a recognized expert in Salesforce services, headquartered in Bengaluru, Karnataka. The company anticipates the transaction will be closed within 4 weeks pending customary closing conditions. This strategic acquisition will significantly help Saksoft expand its capabilities around Salesforce solutions, cloud innovation, and customer experience optimization.
HDFC Life Insurance Company has received approval to raise funds up to Rs 1,500 crore through non-convertible debentures (NCDs). The NCDs, carrying a coupon rate of 8.05% and a 10-year term, are set for allotment on October 9.
Tata Motors has begun construction of a Rs 9,000-crore plant in Tamil Nadu for manufacturing Jaguar Land Rover vehicles. Tata Motors says the new greenfield factory, for which the company will invest about Rs 9,000 crore, will be able to produce over 2.5 lakh vehicles per year at full capacity. Production at the plant will begin in a phased manner and progressively increase to reach this capacity over the next 5-7 years.
Bajel Projects has forayed into the nascent data centre segment securing its first order from an upcoming data center service provider. Bajel has bagged an order for the design and construction of a 220/33 KV Gas Insulated Substation (GIS) Substation and transmission line extension for a colocation data center in Navi Mumbai.
Dr. Reddy's Laboratories has made an investment of $620 million in Dr. Reddy’s Laboratories SA, Switzerland (DRL SA), a wholly-owned subsidiary of the Company and DRL SA has allotted 6,200,000 non-convertible preference shares each with a nominal value of $100 to the company on September 27, 2024.
Alembic Pharmaceuticals has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection carried out by them at its Oral Solid Formulation Facility (F-I) at Panelav from July 17, 2024 to July 26, 2024. With this, for all the company’s USFDA facilities, EIRs are in place.
The USFDA has inspected Lupin’s Pithampur Unit-1 API and finished product manufacturing facility from September 16 to September 27, 2024. The inspection closed with three observations each on the API and Finished Product side. The company is addressing the observations comprehensively and will respond to the USFDA within the stipulated timeframe.
